# HeartSciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/HeartSciences Inc.). ## Overview HeartSciences Inc. is a U.S.-based medical technology company developing AI-enabled electrocardiography tools that aim to make a standard ECG more clinically useful. Its core products are the cloud-based MyoVista Insights platform and the MyoVista wavECG device, both designed to detect a broader range of cardiac conditions, but neither has yet received FDA marketing clearance. ## Products & services • MyoVista Insights cloud ECG platform • AI-ECG algorithms for cardiac screening and diagnosis • MyoVista wavECG resting 12-lead ECG device • ECG data storage, review, and workflow software • Third-party AI-ECG hosting platform - **Cloud ECG management platform** (20%) — MyoVista Insights provides ECG upload, centralized storage, review, and AI algorithm delivery in clinical workflows. - **AI-ECG algorithms** (25%) — Proprietary and licensed algorithms intended to detect cardiac dysfunction and other heart disease conditions. - **MyoVista wavECG device** (30%) — A proprietary resting 12-lead ECG device designed to combine conventional ECG output with AI-derived diagnostic information. - **Consumables and test-related accessories** (15%) — Proprietary electrodes and related components used with the wavECG device on a per-test basis. - **Platform licensing and third-party hosting** (10%) — Hosting and commercialization of third-party AI-ECG algorithms on the MyoVista Insights platform. - MyoVista Insights cloud-native ECG management platform - AI-ECG algorithms for broader cardiac disease detection - MyoVista wavECG resting 12-lead ECG device - Vendor- and device-agnostic ECG workflow and storage software - Platform to host third-party AI-ECG algorithms ## Customers HeartSciences sells into healthcare providers and payors that want better cardiac screening, workflow efficiency, and earlier detection of undiagnosed heart disease. The company specifically targets cardiologists, referring physicians, hospitals, primary care settings, and insurance-related populations such as Medicare Advantage plans. Early customers are also used as clinical workflow adopters while regulatory clearance is pending. - **Hospitals and health systems** (primary) — Buy the cloud platform and, later, the wavECG device to improve ECG workflow, storage, and diagnostic reach. - **Cardiologists and referring physicians** (primary) — Use the platform and device outputs to support diagnosis and referral decisions for cardiac disease. - **Primary care and point-of-care providers** (secondary) — Adopt the device or cloud workflow for front-line screening where faster triage can improve referral quality. - **Managed care and Medicare Advantage ecosystems** (secondary) — Potential buyers or influencers because better detection of heart disease can support risk adjustment and care management. - **Early adopter clinical sites** (emerging) — Pilot the MyoVista Insights platform to validate workflow fit and prepare for future algorithm deployment. - Hospitals and health systems seeking centralized ECG review - Cardiologists and referring physicians who influence adoption - Primary care and point-of-care settings needing faster screening - Medicare Advantage and managed-care populations with risk-adjustment incentives - Early adopter clinical sites testing workflow integration before clearance ## Geography HeartSciences is headquartered in the United States, but its commercialization strategy is global and explicitly designed to work in any care setting worldwide. Current revenue has been limited and was mainly generated outside the United States through distributor relationships during product development, while future U.S. sales depend on FDA clearance and reimbursement. - Headquartered in the United States - Commercial model is intended to be worldwide - Historical revenue came mainly from non-U.S. distributor relationships - U.S. commercialization depends on FDA clearance and reimbursement - International reimbursement varies by country and can slow adoption ## Strategy The company is building a device-agnostic AI-ECG platform first, then layering in its own MyoVista wavECG hardware and proprietary consumables. It is also pursuing third-party algorithm hosting and licensing partnerships, such as the Mount Sinai collaboration, to expand clinical use cases and reduce internal R&D burden. Near term, the key strategic objective is regulatory clearance and workflow adoption; longer term, the goal is recurring revenue from algorithm usage, subscriptions, and consumables. - **FDA clearance and regulatory pathway execution** (short-term) — Commercial sales in the U.S. depend on clearance for the device and future algorithms. - **Clinical workflow adoption and early customer validation** (short-term) — The platform must fit into existing workflows to gain physician and facility acceptance. - **Platform expansion through third-party algorithms** (medium-term) — Hosting external algorithms can increase clinical value and reduce internal development cost. - **Recurring revenue model development** (medium-term) — Subscriptions, algorithm usage, and consumables can create more durable revenue than one-time device sales. - Obtain FDA clearance for MyoVista wavECG and future algorithms - Scale MyoVista Insights as a device-agnostic cloud platform - Use third-party algorithms to broaden indications and speed rollout - Build recurring revenue from subscriptions, usage, and consumables - Leverage clinical partnerships like Mount Sinai for validation ## Risks HeartSciences is still pre-commercial in its core products, so regulatory clearance, reimbursement, and physician acceptance are the main gating factors for future revenue. The company also faces financing risk, going-concern pressure, supplier dependence, and execution risk as it tries to move from development-stage revenue to a scalable clinical product business. - **Regulatory clearance delay or failure** [critical] — The company cannot market the wavECG in the U.S. without FDA clearance, and future algorithms also require regulatory pathways. - **Insufficient funding and going-concern pressure** [critical] — The company has limited cash, recurring losses, and expects to rely on equity financing to continue operations. - **Reimbursement and coverage uncertainty** [high] — Hospitals and payors may not adopt products without coverage, especially for AI-ECG use cases. - **Physician and customer acceptance** [high] — Adoption depends on clinicians believing the products are useful, reliable, and easy to integrate. - **Supplier and manufacturing dependence** [medium] — The device relies on third-party components and assembly, creating quality, cost, and delivery risk. - **Nasdaq listing compliance and dilution** [medium] — Ongoing losses and equity financing can pressure listing status and dilute shareholders. - No FDA clearance yet for core commercial products - Needs additional financing and has going-concern risk - Physician adoption depends on clinical evidence and workflow fit - Reimbursement uncertainty could limit hospital and payor uptake - Third-party manufacturing and supply chain dependence may disrupt launch ## Accounting The company’s accounting is dominated by early-stage revenue recognition, stock-based compensation, and estimates tied to a development-stage business. Because revenue has been minimal and historically linked to distributor relationships outside the U.S., investors should watch how management recognizes product, software, and future algorithm revenue as commercialization begins. - **Revenue recognition for device, software, and algorithm offerings** — Could materially affect reported revenue timing and gross margin - **Stock-based compensation** — Affects operating expenses and net loss - **Going-concern and liquidity disclosures** — Important for solvency assessment and capital-raising expectations - **Fair value measurement of financing instruments** — Can create volatility in other income/expense and equity balances - Very small and irregular revenue base makes period comparisons volatile - Future device, software, and algorithm revenue may have different timing rules - Stock-based compensation is a meaningful non-cash expense - Going-concern and liquidity disclosures are central to financial analysis - Potential impairment and valuation judgments may affect intangibles and equity awards --- *Last updated: 2026-04-28T20:14:35.706550+00:00*